REGULATED EXPRESSION OF TENASCIN AND AVB6 IN ORAL CANCER
口腔癌中腱蛋白和 AVB6 的调控表达
基本信息
- 批准号:2015297
- 负责人:
- 金额:$ 11.02万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1997
- 资助国家:美国
- 起止时间:1997-04-01 至 2002-03-31
- 项目状态:已结题
- 来源:
- 关键词:athymic mouse biomarker cell growth regulation disease /disorder model gene expression genetic regulation glycoprotein structure human tissue immunocytochemistry integrins metastasis monoclonal antibody neoplasm /cancer classification /staging neoplasm /cancer invasiveness neoplastic cell neoplastic growth neoplastic process oral pharyngeal neoplasm receptor expression squamous cell carcinoma tenascin tissue /cell culture
项目摘要
Squamous cell carcinoma (SCC) accounts for approximately 96% or all oral
cancers. SCC has a tendency to be locally invasive as well as to
metastasize widely; the five-year survival rates are less than 50%. Tumor
invasion and metastasis is a complex process involving multiple
interactions between tumor cells and the extracellular matrix (ECM).
Matrix components such as laminin and fibronectin have been studied
extensively regarding their roles in tumor progression. However, other ECM
components also play a role. In particular, we and others have observed
that tenascin-C (TN-C) expression is upregulated in oral cancer. In this
project we propose to investigate how the expression of TN-C and its
receptor, alpha vbeta6, are regulated during oral SCC progression. TN-C is
a large oligomeric glycoprotein that is transiently expressed during
development and is involved in morphogenetic movements, tissue patterning,
and tissue repair. TN-C contains multiple domains, both adhesive and anti-
adhesive, that interact with cells, fibronectin, and other ECM molecules.
There are different isoforms of the molecule, which result from alternative
mRNA splicing.
One receptor for TN-C is alphavbeta6. Several lines of evidence suggest
that the alphav integrin subfamily is important for tumor growth, invasion,
and metastasis. First, recent work has demonstrated that antagonists to
alphavbeta3 inhibit tumor angiogenesis. Second, alphavbeta3 has been shown
to be upregulated in vertically invasive melanoma. Third, alphavbeta6 was
recently found to be neo-expressed in oral SCC, while absent from normal
oral mucosa.
We hypothesize that TN-C and alphavbeta6 play a role in the progression of
oral cancer by acting as co-stimulatory modulators of tumor cell motility,
invasion, or gene expression. The specific aims of this proposal are; (1)
To assess the expression of tenascin-C and its receptor, alphavbeta6, as
potential markers for invasive oral SCC. (2) To determine whether
alterations in the expression of alphavbeta6 will modify the invasive
behavior of oral SCC cells. (3) To evaluate different stages of tumor
invasion, using an animal model, for differential expression of TN-C and
alphavbeta6. These studies should enrich our understanding of how less-
well-characterized matrix proteins like tenascin-C and the alphavbeta6
receptor contribute to oral cancer progression. Being able to identify
those oral SCC tumors likely to be most invasive will help in selecting the
most appropriate treatment modality and may improve the currently grim
prognosis of patients with these tumors.
鳞状细胞癌(SCC)约占96%或全部口腔癌
癌症。鳞状细胞癌有局部侵袭性的倾向,以及
转移范围广;五年存活率不到50%。肿瘤
侵袭和转移是一个复杂的过程,涉及多个
肿瘤细胞与细胞外基质之间的相互作用。
对层粘连蛋白和纤维连接蛋白等基质成分进行了研究
广泛关注它们在肿瘤进展中的作用。然而,其他ECM
组件也起到了作用。特别是,我们和其他人观察到
TN-C在口腔癌中的表达上调。在这
我们计划研究TN-C及其受体的表达如何
受体αvbeta6在口腔鳞状细胞癌进展过程中受到调节。TN-C IS
一种大的寡聚体糖蛋白,在
发育并参与形态发生运动、组织构图、
和组织修复。TN-C含有多个结构域,既有粘性的,也有防粘性的
粘合剂,与细胞、纤维连接蛋白和其他ECM分子相互作用。
分子有不同的异构体,它们是由交替产生的
信使核糖核酸剪接
TN-C的一个受体是αvbeta6。有几行证据表明
整合素α亚家族对肿瘤的生长、侵袭、
和转移。首先,最近的研究表明,拮抗剂可以
αvbeta3抑制肿瘤血管生成。第二,Alphavbeta3已经显示出来了
在垂直侵袭性黑色素瘤中上调。第三,Alphavbeta6是
最近发现在口腔鳞癌中有新的表达,而在正常的口腔鳞癌中没有表达
口腔粘膜。
我们假设TN-C和Alphavbeta6在糖尿病的进展中起作用。
口腔癌作为肿瘤细胞运动的共刺激调节器,
入侵,或基因表达。这项建议的具体目的是:(1)
检测Tenascin-C及其受体Alphavbeta6、AS的表达
侵袭性口腔鳞癌的潜在标志物。(2)确定是否
αvbeta6表达的改变将改变侵袭性
口腔鳞状细胞癌细胞的行为。(3)评价肿瘤的不同分期
侵袭性,使用动物模型,以差异表达TN-C和
阿尔法贝塔6.这些研究应该会丰富我们对如何减少-
特性良好的基质蛋白,如Tenascin-C和Alphavbeta6
受体参与口腔癌的进展。能够辨别出
那些可能是最具侵袭性的口腔鳞癌肿瘤将有助于选择
最合适的治疗方式,并可能改善目前的严峻
这些肿瘤患者的预后。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DANIEL M RAMOS其他文献
DANIEL M RAMOS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DANIEL M RAMOS', 18)}}的其他基金
ORAL MELANOMA: ALPHA V BETA 3 EXPRESSION AND METASTASIS
口腔黑色素瘤:ALPHA V BETA 3 表达和转移
- 批准号:
6379867 - 财政年份:2000
- 资助金额:
$ 11.02万 - 项目类别:
ORAL MELANOMA: ALPHA V BETA 3 EXPRESSION AND METASTASIS
口腔黑色素瘤:ALPHA V BETA 3 表达和转移
- 批准号:
6758507 - 财政年份:2000
- 资助金额:
$ 11.02万 - 项目类别:
ORAL MELANOMA: ALPHA V BETA 3 EXPRESSION AND METASTASIS
口腔黑色素瘤:ALPHA V BETA 3 表达和转移
- 批准号:
6200152 - 财政年份:2000
- 资助金额:
$ 11.02万 - 项目类别:
ORAL MELANOMA: ALPHA V BETA 3 EXPRESSION AND METASTASIS
口腔黑色素瘤:ALPHA V BETA 3 表达和转移
- 批准号:
6619567 - 财政年份:2000
- 资助金额:
$ 11.02万 - 项目类别:
ORAL MELANOMA: ALPHA V BETA 3 EXPRESSION AND METASTASIS
口腔黑色素瘤:ALPHA V BETA 3 表达和转移
- 批准号:
6516516 - 财政年份:2000
- 资助金额:
$ 11.02万 - 项目类别:
MATRIX REMODELING IN ORAL SQUAMOUS CELL CARCINOMA
口腔鳞状细胞癌的基质重塑
- 批准号:
6176024 - 财政年份:1999
- 资助金额:
$ 11.02万 - 项目类别:
MATRIX REMODELING IN ORAL SQUAMOUS CELL CARCINOMA
口腔鳞状细胞癌的基质重塑
- 批准号:
2885570 - 财政年份:1999
- 资助金额:
$ 11.02万 - 项目类别:
Regulatory function of fyn in oral SCC invasion
fyn在口腔鳞状细胞癌侵袭中的调节作用
- 批准号:
6754349 - 财政年份:1997
- 资助金额:
$ 11.02万 - 项目类别:
Regulatory function of fyn in oral SCC invasion
fyn在口腔鳞状细胞癌侵袭中的调节作用
- 批准号:
6611893 - 财政年份:1997
- 资助金额:
$ 11.02万 - 项目类别:
REGULATED EXPRESSION OF TENASCIN AND AVB6 IN ORAL CANCER
口腔癌中腱蛋白和 AVB6 的调控表达
- 批准号:
2897110 - 财政年份:1997
- 资助金额:
$ 11.02万 - 项目类别:
相似国自然基金
基于DNA甲基化交互网络的癌症hallmark挖掘及其在癌症转移biomarker筛选中的应用
- 批准号:61602201
- 批准年份:2016
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
血清miRNAs成为一种新的biomarker在PD诊断中的价值和LRRK2基因调控的机制研究
- 批准号:81170309
- 批准年份:2011
- 资助金额:50.0 万元
- 项目类别:面上项目
非小细胞肺癌Biomarker的Imaging MS研究新方法
- 批准号:30672394
- 批准年份:2006
- 资助金额:30.0 万元
- 项目类别:面上项目
相似海外基金
酸化ストレス応答アポトーシス誘導蛋白のUCに対する新規Biomarker探索と治療への展開
寻找治疗 UC 的氧化应激反应性凋亡诱导蛋白的新生物标志物并开发治疗方法
- 批准号:
24K11919 - 财政年份:2024
- 资助金额:
$ 11.02万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
肝内胆管癌新規Biomarkerの同定及び癌周囲間質を標的とした新規治療開発
鉴定肝内胆管癌的新型生物标志物并开发针对癌周基质的新疗法
- 批准号:
24K19350 - 财政年份:2024
- 资助金额:
$ 11.02万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
収縮能が保たれた心不全の機械学習分類とmicroRNAなどのbiomarkerの探索
机器学习对具有保留收缩性的心力衰竭进行分类并搜索 microRNA 等生物标志物
- 批准号:
24K19007 - 财政年份:2024
- 资助金额:
$ 11.02万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Development of a predictive biomarker for Parkinson's disease
帕金森病预测生物标志物的开发
- 批准号:
MR/Y019415/1 - 财政年份:2024
- 资助金额:
$ 11.02万 - 项目类别:
Research Grant
Sleep and circadian dysfunction in ageing and neurodegeneration: a life course and biomarker study of the British 1946 birth cohort.
衰老和神经退行性疾病中的睡眠和昼夜节律功能障碍:对英国 1946 年出生队列的生命历程和生物标志物研究。
- 批准号:
MR/Y009452/1 - 财政年份:2024
- 资助金额:
$ 11.02万 - 项目类别:
Fellowship
Biomarker-Based Platform for Early Diagnosis of Chronic Liver Disease to Enable Personalized Therapy (LIVERAIM)
基于生物标志物的慢性肝病早期诊断平台,以实现个性化治疗(LIVERAIM)
- 批准号:
10087822 - 财政年份:2024
- 资助金额:
$ 11.02万 - 项目类别:
EU-Funded
Enhanced stratification of COPD patients via integration of a digitally enabled biomarker Point-of-Care test within a Remote Patient Monitoring tool
通过在远程患者监测工具中集成数字化生物标志物即时检测,增强 COPD 患者的分层
- 批准号:
10098600 - 财政年份:2024
- 资助金额:
$ 11.02万 - 项目类别:
Collaborative R&D
QuBIE: Quantitative Biomarker Identification for Non-Endoscopic Prediction and Monitoring of Treatment Response in Eosinophilic Oesophagitis
QuBIE:用于非内镜预测和监测嗜酸性食管炎治疗反应的定量生物标志物鉴定
- 批准号:
10083253 - 财政年份:2024
- 资助金额:
$ 11.02万 - 项目类别:
Collaborative R&D
膵癌腫瘍内線維化に着目した術前化学療法効果予測に関する画像biomarkerの確立
建立预测胰腺癌瘤内纤维化术前化疗效果的影像生物标志物
- 批准号:
24K18824 - 财政年份:2024
- 资助金额:
$ 11.02万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Multi-modal non-invasive biomarker screening for high-risk undiagnosed liver disease
针对高危未确诊肝病的多模式非侵入性生物标志物筛查
- 批准号:
10073169 - 财政年份:2023
- 资助金额:
$ 11.02万 - 项目类别:
Collaborative R&D